A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Amycretin identity.
We added the six Novo Nordisk Phase 3 trials that ClinicalTrials.gov lists under the name zenagamtide, which the previous version did not describe, from registry records PeptideScanner retained on November 15, 2026.
PeptideScanner change date
November 15, 2026
Evidence lane
Profile
Profile summary
Before
An experimental Novo Nordisk GLP-1 and amylin receptor agonist, now named zenagamtide. It is not FDA-approved.
After
An experimental Novo Nordisk GLP-1 and amylin receptor agonist, now named zenagamtide and in registered Phase 3 trials. It is not FDA-approved.
Evidence note
Before
Published randomized trials, each with fewer than 300 participants, report weight loss in early studies and lower HbA1c in a Phase 2 diabetes trial, with common gastrointestinal side effects.
After
Published randomized trials, each with fewer than 300 participants, report weight loss in early studies and lower HbA1c in a Phase 2 diabetes trial, with common gastrointestinal side effects. Phase 3 trials registered as zenagamtide have not reported results.
We added a plain-language reader guide with cited answers, published trial results from our human evidence review, and the 2026 report that renames amycretin zenagamtide.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
Investigational
After
In clinical trials; not FDA-approved
Profile summary
Before
An amylin and GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.
After
An experimental Novo Nordisk GLP-1 and amylin receptor agonist, now named zenagamtide. It is not FDA-approved.
Evidence note
Before
ClinicalTrials.gov lists a Novo Nordisk oral amycretin study as completed, last updated March 5, 2025.
After
Published randomized trials, each with fewer than 300 participants, report weight loss in early studies and lower HbA1c in a Phase 2 diabetes trial, with common gastrointestinal side effects.
Showing the latest 9 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 15, 2026.
PeptideScanner retained ClinicalTrials.gov record NCT07668401 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was amycretin.
PeptideScanner retained ClinicalTrials.gov record NCT07720271 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-09-28, and PeptideScanner's reviewed identity mapping was amycretin.
PeptideScanner retained ClinicalTrials.gov record NCT07797335 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-09-01, and PeptideScanner's reviewed identity mapping was amycretin.
PeptideScanner retained ClinicalTrials.gov record NCT07861100 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was amycretin.
PeptideScanner retained ClinicalTrials.gov record NCT07931495 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was amycretin.
PeptideScanner retained ClinicalTrials.gov record NCT07931547 at 2026-11-15T17:43:02.409Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was amycretin.
PeptideScanner retained PubMed bibliographic metadata for PMID 40550229 at 2026-07-30T18:25:48.707Z. PubMed recorded a metadata revision date of 2025-07-14 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 40550231 at 2026-07-30T18:25:48.707Z. PubMed recorded a metadata revision date of 2025-07-14 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 40550232 at 2026-07-30T18:22:52.359Z. PubMed recorded a metadata revision date of 2025-09-11 and an Entrez history date of 2025-06-23. PeptideScanner associated this retained record with the identity slug amycretin. These dates describe PubMed metadata history, not the article's original publication date.